ARTICLE | Clinical News
Exelon Patch rivastigmine regulatory update
May 6, 2013 7:00 AM UTC
Novartis disclosed in its 1Q13 earnings that EMA approved an expansion of the label of Exelon Patch rivastigmine transdermal patch to include the 13.3 mg/24 hour dose to treat mild to moderately sever...